HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Bone marrow transplantation enters ‘the dawn of a new era’ Alexandra (Sasha) Todak
• Is transplant advisable for all eligible patients with multiple myeloma in first remission?
• APPs can temper expectations of palliative intervention for malignant bowel obstruction Jessica I. Goldberg, RN, MSN, AGPCNP-BC, ACHPN,
• Thinking outside the box: Bringing primary care into the cancer center Nicholas J. Petrelli, MD, FACS
• Oncologists can allay COVID-19 vaccination concerns of patients with cancer, survivors Ryan Lawrence
• ASH president discusses ‘silver lining’ of COVID-19 for hematology practice, research Jennifer Byrne
• Behavioral interventions improve depression symptoms among young breast cancer survivors Jennifer R. Southall
• Policy changes could help address persistent sex disparities in academic promotions Jennifer Byrne
• An ally to female oncologists promotes their work, shares opportunities Jennifer Byrne
• Inaugural symposium aims to foster ‘ongoing dialogue’ about cancer survivors’ unique needs Mark Leiser
• Studies yield new insights into anticoagulant use and COVID-19 outcomes Jennifer Byrne
• Outcomes after reduced-intensity conditioning allogeneic HSCT vary by graft type Mark Leiser
• Letermovir reduces clinically significant cytomegalovirus reactivation after allogeneic HSCT Mark Leiser
• Durable discontinuation of immunosuppressive therapy rare in chronic GVHD Mark Leiser
• Respiratory viral infections an increasing concern in HSCT Mark Leiser
• Fewer PSA screenings linked to increases in advanced prostate cancer diagnoses Ryan Lawrence
• First-line lenvatinib-pembrolizumab combination improves OS, PFS in advanced kidney cancer Alexandra (Sasha) Todak
• Adjuvant nivolumab significantly extends DFS in high-risk bladder cancer Ryan Lawrence
• Atezolizumab-bevacizumab combination provides ‘longest survival seen’ in advanced HCC Alexandra (Sasha) Todak
• Gut microbiome a potential biomarker for nivolumab efficacy in advanced gastric cancer Jennifer R. Southall
• Ivosidenib confers clinical benefit in advanced cholangiocarcinoma subset Jennifer R. Southall
• Circulating tumor DNA predicts relapse risk among patients with colorectal cancer Jennifer R. Southall
• Addition of ipilimumab to pembrolizumab fails to improve outcomes for NSCLC subset Jennifer R. Southall
• Neoadjuvant atezolizumab induces pathologic response in resectable NSCLC Jennifer R. Southall
• Diabetes risk-reduction diet may improve survival outcomes after breast cancer diagnosis Jennifer R. Southall
• FDA panel: Defer decision on pembrolizumab for early-stage triple-negative breast cancer Jennifer R. Southall
• FDA approves Enhertu for gastric cancer subset
• FDA grants breakthrough therapy designation to asciminib for CML
• FDA approves Libtayo for advanced basal cell carcinoma
• Rutgers Cancer Institute of New Jersey appoints immunotherapy chief
• Medical oncologist appointed chair of bladder cancer advisory board
• The University of Texas MD Anderson Cancer Center names chief medical executive
• Miami Cancer Institute appoints deputy director